The investigational drug DEDN6525A, a new antibody-drug conjugate, was safe, tolerable, and showed hints of activity against three forms of melanoma: cutaneous, mucosal, and ocular.
The I-SPY 2 trial identified a neo-adjuvant regimen containing the investigational drug neratinib and standard chemotherapy to be beneficial for HR-negative, HER2-positive primary (nonmetastatic) breast cancer patients.
In women with breast cancer, loss of the tumor suppressor PTEN was a frequent cause of resistance to the investigational drug BYL719, which blocks the activity of a protein called PI3K-alpha.
The quest to improve survival of children with a high-risk brain tumor has led investigators to two drugs already used to treat adults with breast, pancreatic, lung, and other cancers.
A new drug, ceritinib, appears to be effective against advanced ALK-positive non-small cell lung cancer, both in tumors that have become resistant to crizotinib and in those never treated with the older drug.
A patient with advanced bladder cancer experienced a complete response to the drug combination everolimus and pazopanib in a phase 1 clinical trial. Genomic profiling revealed information that could help identify other patients who may respond to everolimus and pazopanib.
A German study of a new drug therapy for chronic lymphocytic leukemia (CLL) was lauded for including elderly persons who had other, coexisting health issues. An accompanying editorial noted that the study population more accurately represented patients with CLL.
What can nurses do to advocate for the use of medications such as lorezepam (Ativan) for anticipatory nausea when the physician is reluctant to prescribe antianxiety or sleep medications?
Biomarkers for the formation and resorption of bone predict outcomes for men with castration-resistant prostate cancer (CRPC).
An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to an early-phase clinical trial.
Patients requesting specific medications are more likely to be prescribed those medications, according to research.
Researchers have discovered that FDA-approved antipsychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma.
A never-before-seen autophagy mechanism induced by the BRAF inhibitors vemurafenib and dabrafenib explains the resistance that melanoma develops to these BRAF inhibitors, according to new research.
In research that could ultimately lead to many new medicines, scientists have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.
By screening a library of US FDA-approved anticancer drugs that previously wouldn't have been considered as a treatment for a rare type of cancer, scientists were surprised to find several potential possibilities.
Many patients skip doses or stop taking medication entirely when their share of the costs becomes too high.
Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified new potential therapeutic targets for a major form of bladder cancer.
A group of prominent health care experts including bioethicists, pharmacists, policymakers, and cancer specialists have proposed concrete steps for preventing shortages of life-saving drugs.
When a patient's share of prescription costs becomes too high, many patients skip doses or stop taking medication entirely, according to new research.
With a deluge of promising new treatments for advanced prostate cancer, a new model of care is needed that emphasizes collaboration between urology and medical oncology clinicians.
Drugs that enhance oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor. These are the latest findings from the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project
An investigational drug improved median survival while reducing risk of disease progression or death in persons with metastatic gastric cancer participating in the phase III REGARD trial.
The FDA approved Perjeta (pertuzumab) for the neoadjuvant treatment of breast cancer, first generic version of Xeloda (capecitabine) has gained FDA approval, and other FDA actions.
Hybrid compounds formed from structural features of the antinausea agent thalidomide and curcumin destroyed multiple myeloma cells in recent lab experiments.
A newly discovered weakness in cancer cells may make them more susceptible to chemotherapy and other treatments.
In a small study, most patients given low doses of azacitidine prior to standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) remained cancer-free for up to 28 months.
A new way of analyzing data acquired in magnetic resonance imaging appears to identify whether or not tumors are responding to anti-angiogenesis therapy.
After 18 years of follow-up, the drug finasteride was shown to reduce the risk for prostate cancer by approximately one third, but did not significantly affect overall survival in men or survival after prostate cancer diagnosis.
The FDA granted marketing approval to an orphan drug for the topical treatment of stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma (CTCL).
Triple-negative breast cancers may be vulnerable to drugs that attack the proteasome. The proteasome is the cellular structure that disposes the waste of the cell by breaking down damaged or unneeded proteins
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|